Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
This activity has been designed to meet the educational needs of the interprofessional team, which includes medical oncologists and pathologists, as well as other healthcare providers, involved in managing patients with NSCLC.
After participating in this educational activity, participants should be better able to:
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Alexander Drilon, MD, faculty for this educational event, receives research grants and manages funds from Foundation, Medicine, Teva, Taiho, GlaxSmithKlein, PharmaMar; receives ownership interest from mBrace; receives royalties for Wolters Kluwer; and receives consulting fees from 14ner/Elevation Oncology, Abbvie, AstraZeneca, Bayer, Boundless Bio, Bristol Myers, Squibb, Boehringer Ingelheim, EcoR1 Capital, LLC, Entos, Ignyta/Genentech/Roche, Innocare, Loxo/Bayer/Lilly, MonteRosa, Novartis, Nuvalent, Regeneron, Springer Healthcare, and Treeline Bio.
Charu Aggarwal, MD, MPH, FASCO, faculty for this educational event, receives research grant and manages funds from Genentech/Roche, Incyte, Macrogenics, Merck Sharp & Dohome, AstraZeneca/Medimmune; and receives consulting fees from Genentech, Lilly, Celgene, Merk, Astra Zeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Regeneron/Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, and Boehringer Ingelheim.
The following planners/reviewers/managers have disclosed:
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
Total CME, LLC, planners and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.
This activity is supported by An independent educational grant from Bristol Myers Squibb.
During the period 3/1/2024 through 3/1/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
Release Date:
Expiration Date:
